FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced upcoming presentations at two major conferences. The company will present at the 2024 ThinkEquity Conference in New York on October 30, 2024, at 10:30 a.m. ET, and at BIO-Europe 2024 in Stockholm on November 5, 2024, at 1:30 p.m. CET.

FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. Their patent portfolio covers various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.

News Market Reaction – FBLG

-1.05%

1 alert

-1.05% News Effect

On the day this news was published, FBLG declined 1.05%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.

2024 ThinkEquity Conference
Date: October 30, 2024
Location: New York, NY
Format: Company Presentation
Time: 10:30 a.m. ET

BIO-Europe 2024
Date: November 5, 2024
Location: Stockholm, Sweden
Format: Company Presentation
Time: 1:30 p.m. CET

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

About FibroBiologics 

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. 

General Inquiries: 
info@fibrobiologics.com 

Investor Relations: 
Nic Johnson 
Russo Partners 
(212) 845-4242 
fibrobiologicsIR@russopr.com 

Media Contact: 
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com 

FAQ

When is FibroBiologics (FBLG) presenting at the 2024 ThinkEquity Conference?

FibroBiologics (FBLG) is presenting at the 2024 ThinkEquity Conference on October 30, 2024, at 10:30 a.m. ET in New York, NY.

What time is FibroBiologics (FBLG) presenting at BIO-Europe 2024?

FibroBiologics (FBLG) is presenting at BIO-Europe 2024 on November 5, 2024, at 1:30 p.m. CET in Stockholm, Sweden.

How many patents does FibroBiologics (FBLG) currently hold?

FibroBiologics (FBLG) holds 160+ US and internationally issued patents/patents pending across various clinical pathways.

What medical conditions does FibroBiologics (FBLG) focus on treating?

FibroBiologics (FBLG) focuses on treating disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer using fibroblast cells and fibroblast-derived materials.